Scinai Immunotherapeutics Reports Q1 2025 Financials
Ticker: SCNI · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, q1-2025, reporting
Related Tickers: SCIN
TL;DR
SCIN dropped Q1 2025 results, check the 6-K.
AI Summary
Scinai Immunotherapeutics Ltd. filed a Form 6-K on June 2, 2025, to report its Q1 2025 financial results, which were announced via press release on May 30, 2025. The filing incorporates this press release by reference.
Why It Matters
This filing provides investors with an update on Scinai's financial performance for the first quarter of 2025, offering insights into the company's operational and financial health.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not introduce new material risks.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report
- May 30, 2025 (date) — Date of press release announcing Q1 2025 financial results
- Q1 2025 (period) — Financial reporting period
- June 2, 2025 (date) — Filing date of the Form 6-K
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the Q1 2025 financial results of Scinai Immunotherapeutics Ltd., which were previously announced in a press release on May 30, 2025.
When were the Q1 2025 financial results announced?
The Q1 2025 financial results were announced via press release on May 30, 2025.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 2, 2025.
What exhibit is incorporated by reference into this filing?
Exhibit 99.1, the press release announcing the Q1 2025 financial results, is incorporated by reference.
What is the former name of Scinai Immunotherapeutics Ltd.?
The former name of Scinai Immunotherapeutics Ltd. was BiondVax Pharmaceuticals Ltd.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding Scinai Immunotherapeutics Ltd. (SCNI).